Overview
Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets medical devices, with a focus on interventional specialties and less-invasive treatments. Its mission is to transform lives through medical solutions that improve health worldwide.[1][2]
The company reports two business segments, MedSurg and Cardiovascular, and its products address conditions across cardiovascular, respiratory, digestive, oncological, neurological and urological care.[3][4] Its global footprint includes headquarters in Massachusetts and regional headquarters in Singapore and France, with manufacturing facilities across several regions and worldwide distribution.[5] Boston Scientific reported 2025 net sales of $20.074 billion, and its official company page reports 59,000 employees worldwide and commercial representation in 127 countries.[6][7] [1][2][3][4][5][6][7]
Products & services
Boston Scientific’s MedSurg products include endoscopy devices such as Resolution 360 and MANTIS hemostatic clips, WallFlex and AXIOS drainage stents, SpyGlass and EXALT single-use scopes, and the OverStitch endoluminal suturing system and Orbera intragastric balloon. Urology products include LithoVue single-use digital flexible ureteroscopes, Lumenis Pulse holmium lasers with MOSES technology, GreenLight and Rezūm therapies for benign prostatic hyperplasia, AMS 700 penile implants, AMS 800 artificial urinary sphincters, SpaceOAR hydrogel, Axonics sacral neuromodulation and Bulkamid urethral bulking. Neuromodulation offerings include WaveWriter Alpha spinal cord stimulation, Intracept nerve ablation for vertebrogenic pain, and Vercise Genus deep-brain stimulation.[4][8][9][10]
Cardiovascular products include OptiCross intravascular ultrasound imaging and AVVIGO+ guidance systems; ROTAPRO atherectomy, WOLVERINE cutting balloons, SYNERGY drug-eluting coronary stents and AGENT drug-coated balloons; and peripheral vascular products including Eluvia drug-eluting stents, Ranger drug-coated balloons, AngioJet thrombectomy and EKOS ultrasound-assisted thrombolysis. WATCHMAN devices provide percutaneous left atrial appendage closure for eligible patients with non-valvular atrial fibrillation. Electrophysiology offerings include FARAPULSE pulsed-field ablation and OPAL HDx mapping and navigation; cardiac rhythm management products include pacemakers, implantable defibrillators, resynchronization devices and insertable cardiac monitors. LATITUDE and BodyGuardian provide remote cardiac monitoring and management capabilities.[11][12][13][14][15][16][17][18][19][20]
For full-year 2025, reported sales were $20.074 billion: Cardiovascular generated $13.250 billion, or approximately 66.0% of sales, and MedSurg generated $6.824 billion, or approximately 34.0%. Reported product-business sales included $2.916 billion in Endoscopy, $2.709 billion in Urology, $1.199 billion in Neuromodulation, $4.639 billion in Interventional Cardiology and Vascular Therapies, $1.958 billion in WATCHMAN, $3.325 billion in Electrophysiology and $2.332 billion in Cardiac Rhythm Management.[21][22] [4][8][9][11][12][13][14][15][16][21][22][10][17][18][19][20]
Geographic presence
In FY2025, Boston Scientific reported net sales of $20.074 billion. By reported sales region, the United States accounted for $12.864 billion (about 64.1%), Europe, Middle East and Africa for $3.451 billion (17.2%), Asia-Pacific for $3.080 billion (15.3%), and Latin America and Canada for $678 million (3.4%). The company reports sales by region rather than by individual country.[23][6]
Boston Scientific identifies Marlborough, Massachusetts, as its world headquarters. Named principal manufacturing locations include sites in Minnesota, Indiana, Georgia, Puerto Rico, Ireland, Costa Rica, Malaysia, and China; named R&D centers include locations in China, India, Costa Rica, and Ireland. The company reports more than 59,000 employees across 53 countries, but does not provide a regional or country-level employee breakdown in the cited information.[24][25][26] [23][6][24][25][26]
Business segments
Boston Scientific’s 2025 Form 10-K reports two business segments: MedSurg and Cardiovascular. For 2025, MedSurg generated approximately $6.829 billion, or 34% of reportable-segment sales, and Cardiovascular generated approximately $13.266 billion, or 66%. These percentages are calculated from segment sales totaling $20.095 billion; the filing separately reconciles that figure to consolidated net sales.[6] The company reports international sales as a geographic statistic, rather than as an additional business segment.[27]
MedSurg comprises Endoscopy, Urology and Neuromodulation. Its areas include minimally invasive gastrointestinal and pancreaticobiliary diagnosis and treatment; urology products for stone management, benign prostatic hyperplasia, prostate cancer and pelvic-floor conditions; and devices for chronic pain and movement disorders.[8][9][11] Cardiovascular includes Interventional Cardiology and Vascular Therapies, WATCHMAN left atrial appendage closure, Electrophysiology, Cardiac Rhythm Management, and Interventional Oncology and Embolization. These businesses address coronary, peripheral and venous disease; heart-rhythm diagnosis and treatment; implantable rhythm-management devices; and cancer therapies including radioembolization and embolization.[12][13][14][15][16][28] [6][6][6][6][27][8][9][11][12][13][14][15][16][28]
Company history
Boston Scientific was founded in 1979 by John Abele and Pete Nicholas to develop less-invasive medical products; its original incorporation filing was made on June 22 of that year. The company’s IPO became effective in May 1992.[29][30][31]
The company expanded its cardiovascular business with the TAXUS drug-eluting stent, launched internationally in 2003 and approved in the United States in 2004. In 2004 it acquired Advanced Bionics, entering neuromodulation, and in 2006 completed its combination with Guidant, adding a cardiac rhythm management business.[32][33][34]
Further portfolio additions included Cameron Health in 2012, bringing the subcutaneous implantable defibrillator system; EndoChoice in 2016; Symetis in 2017; and BTG and Vertiflex in 2019. Michael F. Mahoney became president and CEO in 2012. In 2024, Boston Scientific completed its acquisition of Axonics, extending its sacral neuromodulation business.[35][36][37][38][39][40][41] [29][30][31][32][33][34][35][36][37][38][39][40][41]
Sources
- BOSTON SCIENTIFIC CORP — Full financial report (2026 Q 2)[1][3]
- BOSTON SCIENTIFIC CORP — Full financial report (2025 Y)
- www.bostonscientific.com[7]
- www.bostonscientific.com[10]
- www.bostonscientific.com[17]
- www.bostonscientific.com[18]
- www.bostonscientific.com[19]
- www.bostonscientific.com[20]
- BOSTON SCIENTIFIC CORP — Presentation (2025 Y)[21]
- BOSTON SCIENTIFIC CORP — Presentation (2026 Q 2)[22]
- www.bostonscientific.com[24]
- investors.bostonscientific.com[25]
- www.bostonscientific.com[26]
- news.bostonscientific.com[29]
- investors.bostonscientific.com[30]
- investors.bostonscientific.com[31]
- news.bostonscientific.com[32]
- news.bostonscientific.com[33]
- news.bostonscientific.com[34]
- news.bostonscientific.com[35]
- news.bostonscientific.com[36]
- news.bostonscientific.com[37]
- news.bostonscientific.com[38]
- news.bostonscientific.com[39]
- news.bostonscientific.com[40]
- news.bostonscientific.com[41]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore BOSTON SCIENTIFIC CORP in Finbar ↗